Humana Inc. (NYSE:HUM) had its price objective raised by stock analysts at Morgan Stanley from $269.00 to $276.00 in a research report issued to clients and investors on Thursday. The brokerage presently has an “overweight” rating on the insurance provider’s stock. Morgan Stanley’s price objective indicates a potential upside of 11.58% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Cowen and Company reissued an “outperform” rating and set a $230.00 price target on shares of Humana in a research report on Tuesday, April 25th. Leerink Swann raised their price target on shares of Humana from $250.00 to $265.00 and gave the company an “outperform” rating in a research report on Tuesday, May 30th. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $257.00 price target for the company in a research report on Thursday, May 25th. BidaskClub downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, June 13th. Finally, UBS AG reissued a “neutral” rating and set a $237.00 price target (up previously from $205.00) on shares of Humana in a research report on Wednesday, June 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $244.35.

Humana (NYSE:HUM) traded down 0.02% during trading on Thursday, hitting $247.30. The stock had a trading volume of 382,599 shares. Humana has a 1-year low of $163.50 and a 1-year high of $255.27. The stock’s 50-day moving average price is $240.60 and its 200-day moving average price is $224.06. The company has a market capitalization of $35.74 billion, a P/E ratio of 20.34 and a beta of 0.91.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. During the same period last year, the business earned $2.30 earnings per share. Analysts expect that Humana will post $11.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Morgan Stanley Boosts Humana Inc. (HUM) Price Target to $276.00” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/morgan-stanley-boosts-humana-inc-hum-price-target-to-276-00/1500311.html.

In other news, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now directly owns 8,150 shares in the company, valued at approximately $1,890,474. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares in the company, valued at $3,421,920. The disclosure for this sale can be found here. Insiders have sold a total of 41,406 shares of company stock worth $10,355,086 over the last 90 days. Corporate insiders own 0.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of Humana by 2,281.7% in the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock valued at $2,553,487,000 after buying an additional 11,867,056 shares in the last quarter. FMR LLC increased its position in shares of Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock valued at $1,041,184,000 after buying an additional 1,851,197 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Humana by 7,848.8% in the second quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock valued at $377,192,000 after buying an additional 1,547,866 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock valued at $554,867,000 after buying an additional 1,231,400 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock valued at $159,915,000 after buying an additional 747,557 shares during the last quarter. Hedge funds and other institutional investors own 99.13% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.